Helicobacter pylori(HP) is a gram-negative, spiral-shaped microaerophilic bacterium. HP may be a lifelong bacterial infection of the gastric mucosa that is primarily acquired during childhood.
HP infection (HP-I) is a widespread infection in humans, and its prevalence is positively correlated with population age. The seroprevalence of HP-I was positively observed in ～50% of the world’s population, and the results indicated higher numbers of HP-I in developing than in developed countries. Large proportions of Asian populations, particularly the Chinese, Japanese, and Korean populations, are infected with HP. HP-I can cause various diseases, such as chronic gastritis, peptic ulcers and gastric cancer. In addition, HP has been associated both epidemiologically and
pathogenetically with coronary atherosclerosis, but data on the relationship between chronic HP-I and ischemic stroke (IS) are conflicting. Stroke is the leading cause of death and disability for both men and women worldwide, and IS is the most common type of stroke. Identifying potential risk factors is an effective method for preventing IS.
It proves that chronic HP-I is significantly associated with an increased risk of IS, particularly nonembolic IS. Anti-HP therapy may have a beneficial influence on IS prevention. An additional ideal prospective trial that examines the association of HP-I with IS, involving antibacterial and antiinflammatory therapy, may provide definitive proof.